| 01:38a | Relief Therapeutics Signs $56 Million Share Subscription Facility With Shareh.. | MT |
| 01:04a | RELIEF THERAPEUTICS : Announces Implementation of New Share Subscription Facilit.. | PU |
| 01:02a | EQS-NEWS : Relief Announces Implementation of New Share Subscription Facility wi.. | DJ |
| 01/20 | GLOBAL MARKETS LIVE: Jack Ma reappears, Better-than-expected profits for Morg.. | |
| 01/20 | Relief Therapeutics Stock Gains 6% on $55 Million Deal to Acquire AdVita Life.. | MT |
| 01/20 | RELIEF THERAPEUTICS : and AdVita Sign Binding Term Sheet for to Acquire All Shar.. | PU |
| 01/20 | EQS-NEWS : Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All S.. | DJ |
| 01/11 | RELIEF, NEURORX AND QUANTUM LEAP ANN : aviptadil) in the I-SPY COVID-19 Trial | PU |
| 01/11 | NeuroRx, RELIEF THERAPEUTICS Signs Contract To Include COVID-19 Drug In I-SPY.. | MT |
| 01/11 | EQS-NEWS : Relief, NeuroRx and Quantum Leap announce the inclusion of ZYESAMI(TM.. | DJ |
| 01/11 | NEURORX, RELIEF, AND QUANTUM LEAP AN : aviptadil) in the I-SPY COVID-19 Trial | PR |
| 01/11 | EQS-NEWS : Relief, NeuroRx and Quantum Leap -2- | DJ |
| 2020 | RELIEF THERAPEUTICS : stock plunges after FDA rejects COVID-19 emergency approva.. | RE |
| 2020 | Relief Therapeutics, NeuroRx Finish Enrollment for COVID-19 Treatment Trial | MT |
| 2020 | RELIEF THERAPEUTICS : and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial .. | PU |
| 2020 | NEURORX : and Relief Conclude Enrollment in their Phase 2b/3 Trial of RLF-100&tr.. | PR |
| 2020 | EQS-NEWS : Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of R.. | DJ |
| 2020 | Relief Therapeutics Names Chief Commercial Officer | MT |
| 2020 | RELIEF THERAPEUTICS : Appoints Chris L.J.J. Stijnen as Chief Commercial Officer | PU |
| 2020 | EQS-NEWS : Relief Appoints Chris L.J.J. Stijnen as Chief Commercial Officer | DJ |
| 2020 | RELIEF THERAPEUTICS : Announces Results of Extraordinary General Meeting of THER.. | PU |
| 2020 | RELIEF THERAPEUTICS : Announces Results of Extraordinary General Meeting of THER.. | EQ |
| 2020 | EQS-NEWS : Relief Announces Results of Extraordinary General Meeting of RELIEF T.. | DJ |
| 2020 | GLOBAL MARKETS LIVE: MasterCard, Volkswagen, Goldman Sachs… | |
| 2020 | Relief Therapeutics, NeuroRx Meet Patients Enrollment Target in Study of COVI.. | MT |
| 2020 | RELIEF THERAPEUTICS : and NeuroRx Meet 165 Patient Enrollment Target in Phase 2b.. | PU |
| 2020 | EQS-NEWS : Relief Therapeutics and NeuroRx Meet -2- | DJ |
| 2020 | EQS-NEWS : Relief Therapeutics and NeuroRx Meet 165 Patient Enrollment Target in.. | DJ |
| 2020 | CORRECTION : NeuroRx and Relief announce initial successful results from expande.. | PU |
| 2020 | CORRECTION : NeuroRx and Relief announce initial successful results from expande.. | EQ |
| 2020 | EQS-NEWS : Correction: NeuroRx and Relief announce -2- | DJ |
| 2020 | EQS-NEWS : Correction: NeuroRx and Relief announce initial successful results fr.. | DJ |
| 2020 | NEURORX AND RELIEF ANNOUNCE INITIAL : 72% survival seen in ICU patients | PR |
| 2020 | NEURORX AND RELIEF ANNOUNCE INITIAL : 72% survival seen in ICU patients | PU |
| 2020 | NEURORX AND RELIEF ANNOUNCE INITIAL : 72% survival seen in ICU patients | EQ |
| 2020 | RELIEF THERAPEUTICS : Announces Notice of Extraordinary General Meeting of THERA.. | PU |
| 2020 | RELIEF THERAPEUTICS : Announces Notice of Extraordinary General Meeting of THERA.. | EQ |
| 2020 | Relief Therapeutics Hires Clinical Researcher for European Trial of COVID-19 .. | MT |
| 2020 | RELIEF THERAPEUTICS : Selects CRO and CDMO for RLF-100TM in Europe | PU |
| 2020 | RELIEF THERAPEUTICS : Selects CRO and CDMO for RLF-100TM in Europe | EQ |
| 2020 | NEURORX : and Relief Therapeutics announce enrollment of 150 patients in phase 2.. | PR |
| 2020 | Relief Therapeutics, NeuroRx Register 150 Patients in Clinical Trial for COVI.. | MT |
| 2020 | RELIEF THERAPEUTICS : with Partner NeuroRx, Announces Enrollment of 150 Patients.. | PU |
| 2020 | RELIEF THERAPEUTICS : with Partner NeuroRx, Announces Enrollment of 150 Patients.. | EQ |
| 2020 | RELIEF THERAPEUTICS : pushes back data release date for COVID-19 study to Januar.. | RE |
| 2020 | RELIEF THERAPEUTICS AND NEURORX ANNO : Trial is on track to complete enrollment .. | PU |
| 2020 | NEURORX AND RELIEF THERAPEUTICS ANNO : Trial is on track to complete enrollment .. | PR |
| 2020 | RELIEF THERAPEUTICS AND NEURORX ANNO : Trial is on track to complete enrollment .. | EQ |
| 2020 | RELIEF THERAPEUTICS : Appoints J. Paul Waymack, M.D., Sc.D. as Consultant to Str.. | PU |
| 2020 | RELIEF THERAPEUTICS : Appoints J. Paul Waymack, M.D., Sc.D. as Consultant to Str.. | EQ |
| 2020 | RELIEF THERAPEUTICS : NeuroRx and Relief announce topline efficacy data from pat.. | PU |
| 2020 | RELIEF THERAPEUTICS : says some COVID-19 patients who got its drug survived long.. | RE |
| 2020 | NEURORX : and Relief announce topline efficacy data from patients treated with R.. | PR |
| 2020 | RELIEF THERAPEUTICS : NeuroRx and Relief announce topline efficacy data from pat.. | EQ |
| 2020 | RELIEF THERAPEUTICS : Appoints Industry Veteran, Jack Weinstein, as Chief Financ.. | EQ |
| 2020 | RELIEF THERAPEUTICS : NeuroRx and Relief Therapeutics Establish Supply and Distr.. | EQ |
| 2020 | RELIEF THERAPEUTICS : Announces Capital Increase from its Final Tranche of the S.. | PU |
| 2020 | RELIEF THERAPEUTICS : deal with biggest owner lifts cash to $52 mln for COVID-19.. | RE |
| 2020 | RELIEF THERAPEUTICS : deal with biggest owner lifts cash to $52 mln for COVID-19.. | RE |
| 2020 | RELIEF THERAPEUTICS : Announces Capital Increase from its Final Tranche of the S.. | EQ |
| 2020 | New Covid-19 vaccine developments | |
| 2020 | RELIEF THERAPEUTICS : partner NeuroRx submits request for Emergency Use Authoriz.. | PU |
| 2020 | RELIEF THERAPEUTICS : partner NeuroRx submits request for Emergency Use Authoriz.. | EQ |
| 2020 | NEURORX : submits request for Emergency Use Authorization for RLF-100™ (av.. | PR |
| 2020 | UBS eying new acquisition, Deutsche Bank’s suspicious transactions… | |
| 2020 | RELIEF THERAPEUTICS : and NeuroRx Announce Partnership for Global Commercializat.. | PU |
| 2020 | RELIEF THERAPEUTICS : and NeuroRx Announce Partnership for Global Commercializat.. | PR |
| 2020 | RELIEF THERAPEUTICS : and NeuroRx Announce Partnership for Global Commercializat.. | EQ |
| 2020 | RELIEF THERAPEUTICS : Condensed consolidated interim financial statements for th.. | PU |
| 2020 | RELIEF THERAPEUTICS : Reports Half-Year 2020 Results | PU |
| 2020 | RELIEF THERAPEUTICS : sees top-line trial results for COVID-19 treatment in earl.. | RE |
| 2020 | RELIEF THERAPEUTICS : Reports Half-Year 2020 Results | EQ |
| 2020 | RELIEF THERAPEUTICS : Appoints Gilles Della Corte, M.D. as Chief Medical Officer | PU |
| 2020 | RELIEF THERAPEUTICS : Appoints Gilles Della Corte, M.D. as Chief Medical Officer | EQ |
| 2020 | RELIEF THERAPEUTICS : Announces Successful Up-listing from OTC Pink to OTCQB and.. | PU |
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
